Claim Filing, Review, and Approval Process Sample Clauses

Claim Filing, Review, and Approval Process. 1. Claim Form To submit a valid Claim, Settlement Class Members must correctly provide all the information and documentation required by the Claim Form. The Claim Form shall require any Settlement Class Member who submits a Claim to provide the following documentation and information, and affirm that the documents and information provided are true and accurate under penalty of perjury: (a) Settlement Class Claimant’s name, current address, telephone number, and e-mail address; (b) Settlement Class Claimant’s telephone number that received a text message from any one of the Released Parties; (c) an affirmation that the Settlement Class Claimant received a text message from any one of the Released Parties within the Class Period; and (d) a declaration under penalty of perjury that all information and representations contained in the Claim Form are true and correct.
Sample 1
AutoNDA by SimpleDocs
Claim Filing, Review, and Approval Process. 1. Claim Form To submit a valid Claim, Settlement Class Members must correctly provide all the information and documentation required by the Claim Form. The Claim Form shall require any Settlement Class Member who submits a Claim to provide the following documentation and information, and affirm that the documents and information provided are true and accurate under penalty of perjury: (i) the Settlement Class Member's full name, address, and other information, as necessary, to allow the Administrator to contact the Settlement Class Member to validate the Claim, if necessary; (ii) the telephone number at which Lexington and/or a third party lead generator allegedly contacted the Settlement Class Member; (iii) affirmation, under penalty of perjury, that the Settlement Class Member received one or more telephone calls and/or text messages from Lexington and/or a third party lead generator to the Settlement Class Member's cellular telephone on or after July 12, 2013, through the date of the entry of an order of preliminary approval by the Court (the "Preliminary Approval Order"), and the Settlement Class Member either did not give prior express written consent to be called or the Settlement Class Member claims that the prior express written consent was not contextually sufficient to initiate a telemarketing sales call; (iv) for emailed Claim Forms, the Settlement Class Member's signature; and (v) for Claim Forms submitted via the Settlement Website, the Settlement Class Member's electronic signature. Only one valid Claim Form will be honored per Settlement Class Member, regardless of the number of calls or text messages the Settlement Class Member received. Lexington shall have the right to review and research the submitted Claim Forms and to suggest denial of claims if Lexington has a good faith belief that such claims are improper or fraudulent. Any suggestion of denial of claims shall be provided to Class Counsel in writing. If the Parties cannot agree upon which claims should be denied then they shall submit the issue to the Court for determination in connection with Final Approval.
Sample 1
Claim Filing, Review, and Approval Process. 1. Claim Form To submit a valid Claim, Settlement Class Members must correctly provide all the information and documentation required by the Claim Form. The Claim Form shall require any Settlement Class Member who submits a Claim to provide the following documentation and information, and affirm that the documents and information provided are true and accurate under penalty of perjury: (a) Settlement Class Claimant’s name, current address, telephone number, and e-mail address; (b) Settlement Class Claimant’s telephone number that received a text message from Colourpop; (c) an affirmation that the Settlement Class Claimant received a text message from Colourpop within the Class Period; and (d) a declaration under penalty of perjury that all information and representations contained in the Claim Form are true and correct.
Sample 1
Claim Filing, Review, and Approval Process. 1. Claim Form For Class Members Identified on the Settlement Class List (Member With Unique Numerical Identifier) For Settlement Class Members identified on the Settlement Class List and assigned a unique numerical identifier, to submit a valid Claim they must correctly provide all of the information and documentation required by the Claim Form attached as Exhibit A. The Claim Form shall require any such Settlement Class Member who submits a Claim to provide the following information, and affirm, via a Check Box, that the information provided is true and accurate under penalty of perjury:
Sample 1
Claim Filing, Review, and Approval Process. 1. Claim Form To submit a Claim, Settlement Class Members must correctly provide the information and documentation required by the Claim Form. The Claim Form shall require any Settlement Class Member who submits a Claim to provide the following documentation and information: (a) Settlement Class Claimant’s name, current address, telephone number, and e-mail address (if any);
Sample 1
Claim Filing, Review, and Approval Process. 1. Claim Form To submit a valid Claim, Settlement Class Members must correctly provide all the information and documentation required by the Claim Form. The Claim Form shall require any Settlement Class Member who submits a Claim to provide the following documentation and information: (a) Settlement Class Claimant’s name and address; (b) Settlement Class Claimant’s telephone number that received a text message from Defendants; and (c) an affirmation that the Settlement Class Claimant received a text message from Defendants within the Class Period, without prior express written consent. For persons who did not receive Mail Notice but who otherwise submit a Claim Form, such persons must provide a telephone number that matches a telephone number on the Class List.
Sample 1
Claim Filing, Review, and Approval Process 
Sample 1Sample 2
AutoNDA by SimpleDocs

Related to Claim Filing, Review, and Approval Process

  • Review and Approval Documents specified above must be submitted for review and approval by CITY Purchasing and Contracts prior to the commencement of work by CONTRACTOR. Neither approval by CITY nor failure to disapprove the insurance furnished by CONTRACTOR shall relieve CONTRACTOR of CONTRACTOR’S full responsibility to provide the insurance required by this Contract. Compliance with the insurance requirements of this Contract shall not limit the liability of CONTRACTOR or its sub-contractors, employees or agents to CITY or others, and shall be in addition to and not in lieu of any other remedy available to CITY under this Contract or otherwise. CITY reserves the right to request and review a copy of any required insurance policy or endorsement to assure compliance with these requirements.

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.

  • Development Reports Beginning six months after Effective Date and ending on the date of first commercial sale of a Licensed Product in the United States, LICENSEE shall report to Cornell progress covering LICENSEE's (and Affiliate's and Sublicensee's) activities and efforts in the development of rights granted to LICENSEE under this Agreement for the preceding six months. The report shall include, but not be limited to, activities and efforts to develop and test all Licensed Products and obtain governmental approvals necessary for marketing the same. Such semi-annual reports shall be due within sixty days (60) of the reporting period and shall use the form as provided herein as Appendix C.

  • Due Diligence Review; Information The Company shall make available, during normal business hours, for inspection and review by the Investors, advisors to and representatives of the Investors (who may or may not be affiliated with the Investors and who are reasonably acceptable to the Company), all financial and other records, all SEC Filings (as defined in the Purchase Agreement) and other filings with the SEC, and all other corporate documents and properties of the Company as may be reasonably necessary for the purpose of such review, and cause the Company’s officers, directors and employees, within a reasonable time period, to supply all such information reasonably requested by the Investors or any such representative, advisor or underwriter in connection with such Registration Statement (including, without limitation, in response to all questions and other inquiries reasonably made or submitted by any of them), prior to and from time to time after the filing and effectiveness of the Registration Statement for the sole purpose of enabling the Investors and such representatives, advisors and underwriters and their respective accountants and attorneys to conduct initial and ongoing due diligence with respect to the Company and the accuracy of such Registration Statement. The Company shall not disclose material nonpublic information to the Investors, or to advisors to or representatives of the Investors, unless prior to disclosure of such information the Company identifies such information as being material nonpublic information and provides the Investors, such advisors and representatives with the opportunity to accept or refuse to accept such material nonpublic information for review and any Investor wishing to obtain such information enters into an appropriate confidentiality agreement with the Company with respect thereto.

  • Tests and Preclinical and Clinical Trials The studies, tests and preclinical and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder (collectively, “FFDCA”); the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the General Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate in all material respects and fairly present the data derived from such studies, tests and trials; except to the extent disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company is not aware of any studies, tests or trials, the results of which the Company believes reasonably call into question the study, test, or trial results described or referred to in the Registration Statement, the General Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical state of development; and, except to the extent disclosed in the Registration Statement, the General Disclosure Package or the Prospectus, neither the Company nor any Subsidiary has received any notices or correspondence from the FDA or any Governmental Entity requiring the termination or suspension of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

  • Completion of Review for Certain Review Receivables Following the delivery of the list of the Review Receivables and before the delivery of the Review Report by the Asset Representations Reviewer, the Servicer may notify the Asset Representations Reviewer if a Review Receivable is paid in full by the Obligor or purchased from the Issuer in accordance with the terms of the Basic Documents. On receipt of such notice, the Asset Representations Reviewer will immediately terminate all Tests of the related Review Receivable, and the Review of such Review Receivables will be considered complete (a “Test Complete”). In this case, the related Review Report will indicate a Test Complete for such Review Receivable and the related reason.

  • Adverse Event Reporting Both Parties acknowledge the obligation to comply with the Protocol and / or applicable regulations governing the collection and reporting of adverse events of which they may become aware during the course of the Clinical Trial. Both Parties agree to fulfil and ensure that their Agents fulfil regulatory requirements with respect to the reporting of adverse events.

Time is Money Join Law Insider Premium to draft better contracts faster.